- Home
- PBT vs EYPT Comparison
PBT vs EYPT Comparison
Compare PBT & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBT | EYPT |
|---|---|---|
| Founded | 1980 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Laboratory Analytical Instruments |
| Sector | Energy | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 799.8M | 1.5B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | PBT | EYPT |
|---|---|---|
| Price | $17.55 | $16.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $29.60 |
| AVG Volume (30 Days) | 70.4K | ★ 1.2M |
| Earning Date | 03-13-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | $17,266,423.00 | ★ $42,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $53.02 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.01 | $3.91 |
| 52 Week High | $20.46 | $19.11 |
Technical Indicators
Market Signals| Indicator | PBT | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 51.82 | 51.46 |
| Support Level | $16.78 | $16.67 |
| Resistance Level | $17.83 | $18.50 |
| Average True Range (ATR) | 0.61 | 0.98 |
| MACD | 0.09 | -0.23 |
| Stochastic Oscillator | 88.57 | 22.26 |
Price Performance
Historical ComparisonAbout PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.